The Reform That Promises to Cure the Price of Health Insurance

One number captures the moment Mexico is living through: In 2026, renewing a major medical expense policy can cost up to 75% more than the year before. This is not an isolated case or a one-off abuse. It is the visible symptom of a system that has been sick for years and that, for the first time, has Congress, insurers, and hospitals sitting at the same table. The uncomfortable question is whether that table is debating the right cure or simply fighting over who pays the bill.

What Is on the Table

Since February 2025, a bill championed by congressman Jericó Abramo Masso and backed, unusually, by nearly every party: the PAN, Movimiento Ciudadano, the PVEM, and Morena,  proposes to rewrite the rules of private health insurance. Its most ambitious points are anything but minor.

First, a cap on premium increases for people over 60, financed by an amortization fund fed by the policies of younger members. Second, mandatory transparency: insurers would have to disclose rates, agent commissions, pricing-adjustment criteria, and any change to their medical network fifteen business days in advance. Third, portability of seniority, so that switching insurers no longer means losing the pre-existing-condition coverage a policyholder has already earned. Add to that the option to choose doctors outside the network by paying a differential, coverage of medicines and surgical supplies, and expanded powers for Condusef and Profeco, Mexico's consumer-protection regulators.

To the consumer, it sounds like everything they have always asked for. To the industry, it sounds like someone just touched the heart of the actuarial model.

The Freeze and Its Rumors

This is where the story gets interesting. The bill had a committee opinion ready in the Finance Commission. And then, on April 28, it was frozen. The official version is cautious: the Finance Ministry asked for more time, citing the impact on tax revenue and on the sector's viability, and AMIS  the insurers' association  backed the delay, calling for "a deeper technical analysis that puts the patient at the center."

The unofficial version is sharper. Industry columnists now speak openly of "soft regulatory capture." While the reform was rhetoric about protecting the user, no one stopped it; the moment it grew teeth;  hospital billing, real portability, penalties., the brake appeared. Abramo himself was blunter, charging that the pause would let insurers raise rates preemptively before the law could stop them. As one sector analyst put it: Throughout this negotiation, insurers, hospitals, doctors, and legislators all kept their ground. The only one who lost was the patient.

The resolution will not take long. Senate leader Ricardo Monreal has announced that the reform will be a priority in the ordinary session that begins on Sept. 1, 2026, and the Chamber expects to unfreeze it. In the coming weeks, this debate returns to the spotlight.

A Diagnostic Error

And here is my deeper concern, the one almost no one at that table is saying out loud: the reform is fighting the price, not what produces it.

The price of a policy does not rise on a whim. It rises because medical inflation in Mexico runs between 12% and 16% a year, far above general inflation. It rises because private spending already represents 41% of the country's total health expenditure,  (one of the highest shares in the OECD)  meaning that millions of Mexicans pay out of pocket for a system the public sector cannot cover. It rises because there are overbilled procedures, specialty drugs with no price controls, and a brutal information asymmetry between the party charging and the party paying.

Capping the premium without addressing those causes is like lowering a patient's fever without treating the infection. The number looks better for a while; the disease keeps advancing. Worse still: if you regulate the price without solving the cause, the real risk is that insurers cut coverage, tighten pre-existing-condition clauses, or simply stop selling policies to the least profitable segments. Protection turns into exclusion.

The Lever No One Is Putting on the Table

There is a tool capable of attacking the cause and not just the symptom, and it is precisely the one absent from the legislative debate: digital health.

The transparency the reform wants to impose by decree, technology can already deliver in real time: price comparators for procedures, interoperable electronic health records, and data that strip hospital billing of its zone of opacity. The cost containment insurers say they need will not come from an imposed rate table, but from data-driven prevention: telemedicine that avoids costly hospitalizations, remote monitoring of the chronic diseases that consume the bulk of spending, and risk models that reward the patient who stays healthy instead of punishing the one who ages.

Put differently: Congress is debating how to divide a shrinking pie, when the conversation that matters is how to stop the pie from shrinking. And that conversation is digital.

What Comes Next

Mexico is weeks away from a reform that, in its current form, will make public opinion feel good and likely move the needle very little on the real problem. I am not against transparency or protecting older adults; both are urgent and just. But if the underlying goal is to make private health care affordable again, price regulation is, at best, half the answer.

The other half, the one that could keep us from talking about double-digit increases again in 2027  lies in digitizing health, measuring what today goes unmeasured, and preventing what today is only treated late and expensively. Let us hope legislators, insurers, and hospitals grasp this before passing a law that treats the symptom and forgets the disease.